Interstitial Lung Disease Trial, Recruiting (NCT07457463)

Interstitial Lung Disease Trial, Recruiting NCT07457463 Sponsor: Insel Gruppe AG, University Hospital Bern Condition: Interstitial Lung Disease

Printed from Voxsanity (voxsanity.com.au) — NCT07457463 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Interstitial Lung Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with a fibrotic interstitial lung disease (a type of lung scarring condition) as the main reason for attending pulmonary rehabilitation (this applies to participants at Berner Reha Zentrum only)
People who are already enrolled in a specific lung disease research study (the Idiopathic Interstitial Pneumonia cohort study, reference Nr. 246/15 / PB_2016-01524) and have agreed to allow their data to be used for further research (this applies to participants at Inselspital only)
People aged 18 years or older
People who have provided written agreement to take part in the study

Who may not be able to join:

People who have difficulty understanding information or following study instructions due to cognitive challenges, or who do not have sufficient knowledge of German (the language used in this study)
People who have a diagnosis of sarcoidosis (a specific inflammatory condition that affects multiple organs)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 15 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Thimo Marcin, PHD, Center for Rehabilitation & Sports Medicine Inselspital and Berner Reha Zentrum, Bern University Hospital, University of Bern, Switzerland

Phone: +41 33 244 3048

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07457463

Sponsor: Insel Gruppe AG, University Hospital Bern

Phase: Not Applicable

Status: Recruiting

Condition: Interstitial Lung Disease

Trial contact: +41 33 244 3048

More information: https://clinicaltrials.gov/study/NCT07457463

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with a fibrotic interstitial lung disease (a type of lung scarring condition) as the main reason for attending pulmonary rehabilitation (this applies to participants at Berner Reha Zentrum only)
People who are already enrolled in a specific lung disease research study (the Idiopathic Interstitial Pneumonia cohort study, reference Nr. 246/15 / PB_2016-01524) and have agreed to allow their data to be used for further research (this applies to participants at Inselspital only)
People aged 18 years or older
People who have provided written agreement to take part in the study

Who may not be able to join:

People who have difficulty understanding information or following study instructions due to cognitive challenges, or who do not have sufficient knowledge of German (the language used in this study)
People who have a diagnosis of sarcoidosis (a specific inflammatory condition that affects multiple organs)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 15 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Insel Gruppe AG, University Hospital Bern

Registry

ClinicalTrials.gov

Start date

7 October 2025

Est. completion

1 August 2027

Where this trial is recruiting

🇨🇭 Switzerland

Primary endpoints

Intervention feasibility outcomes - Acceptance; Intervention feasibility outcomes - Appropriateness; Intervention feasibility outcomes - Feasibiilty; Intervention feasibility outcomes - Compliance; Intervention feasibility outcomes - Farriers and facilitators

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov